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A Combined Therapeutic Regimen
of Buspirone and Environmental Enrichment
Is More Efficacious than Either Alone in Enhancing
Spatial Learning in Brain-Injured Pediatric Rats
Christina M. Monaco,1,2 Kory M. Gebhardt,1,2 Sarah M. Chlebowski,1,2 Kaitlyn E. Shaw,1,2
Jeffrey P. Cheng,1,2 Jeremy J. Henchir,2 Margaret F. Zupa,7 and Anthony E. Kline1–6
Abstract
Buspirone, a 5-HT1A receptor agonist, and environmental enrichment (EE) enhance cognition and reduce histopathology
after traumatic brain injury (TBI) in adult rats, but have not been fully evaluated after pediatric TBI, which is the leading
cause of death in children. Hence, the aims of this study were to assess the efficacy of buspirone alone (Experiment 1) and
in combination with EE (Experiment 2) in TBI postnatal day-17 male rats. The hypothesis was that both therapies would
confer cognitive and histological benefits when provided singly, but their combination would be more efficacious.
Anesthetized rats received a cortical impact or sham injury and then were randomly assigned to receive intraperitoneal
injections of buspirone (0.08mg/kg, 0.1mg/kg, and 0.3mg/kg) or saline vehicle (1.0mL/kg) 24 h after surgery and once
daily for 16 days (Experiment 1). Spatial learning and memory were assessed using the Morris water maze (MWM) on
post-operative days 11–16, and cortical lesion volume was quantified on day 17. Sham controls for each condition were
significantly better than all TBI groups. In the TBI groups, buspirone (0.1mg/kg) enhanced MWM performance versus
vehicle and buspirone (0.08mg/kg and 0.3mg/kg) ( p < 0.05) and reduced lesion volume relative to vehicle ( p = 0.038). In
Experiment 2, buspirone (0.1mg/kg) or vehicle was combined with EE after TBI, and the data were compared to the
standard (STD)-housed groups from Experiment 1. EE lead to a significant enhancement of spatial learning and a
reduction in lesion size versus STD. Moreover, the combined treatment group (buspirone +EE) performed markedly better
than the buspirone + STD and vehicle +EE groups, which suggests an additive effect and supports the hypothesis. The data
replicate previous studies assessing these therapies in adult rats. These novel findings may have important rehabilitation-
relevant implications for clinical pediatric TBI.
Key words: 5-HT1A receptor agonist, beam-walking; behavior; controlled cortical impact (CCI); functional recovery;
hippocampus; learning and memory; Morris water maze; traumatic brain injury
Introduction
Traumatic brain injury (TBI) is a significant health care issueworldwide with an estimated 10 million cases annually and 1.7
million of those occurring in the United States.1–5 Children comprise
one of the high-risk groups for TBI.1 Specifically, 475,000 children
under the age of 15 acquire a TBI each year, of which 37,000 are
hospitalized, and more than 2600 do not survive, making it the
leading cause of death and disability in the pediatric population.6–8
Of the surviving children, it is estimated that approximately half
exhibit physical, cognitive, and/or psychosocial deficits.8–10 Because
of the devastating consequences induced by TBI in a population that
could be negatively affected for decades, studies that focus on
functional recovery after pediatric TBI are critical.
Numerous pharmacotherapies, acting on various neurotrans-
mitter systems, have been examined as treatments for functional
outcome after experimental TBI.11–14 One class of drugs that has
received attention is the serotonin1A (5-HT1A) receptor agonists.
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The 5-HT system, and in particular the 5-HT1A receptor subtype, is
an integral component of cognitive processing.15–17 Several studies
have shown that systemic administration of early-and-single (i.e.,
acute) as well as delayed-and-multiple (i.e., chronic) treatments
with the 5-HT1A receptor agonists repinotan HCL and 8-hydroxy-
2-(di-n-propylamino)tetralin (8-OH-DPAT) confer neurobeha-
vioral benefits after TBI.18–24 More recently, buspirone, also a 5-
HT1A receptor agonist, has been reported to enhance cognitive
performance as well as significantly reduce cortical lesion volume
after TBI.25,26 This therapeutic paradigm, however, has not been
evaluated as a treatment for experimental pediatric brain injury.
In addition to pharmacotherapies, noninvasive approaches have
also been investigated after TBI. Environmental enrichment (EE),
in particular, has been evaluated extensively in adult, and to a much
lesser extent, in pediatric rodents as a pre-clinical model of neu-
rorehabilitation. EE consists of expansive accommodations, which
include cognitive and social stimulation that results in the reduction
of histological damage and enhancement of functional recovery27
induced by either controlled cortical impact (CCI)20,23,26–34 or fluid
percussion.35–40
Given that the 5-HT1A receptor agonist buspirone and EE confer
recovery in adult rats after brain trauma, the goals of this study were
to evaluate the potential efficacy of these therapies alone and in
combination after pediatric TBI. It was hypothesized that buspirone
and EE will attenuate histological damage and enhance cognitive
recovery after CCI injury, but the combination will be more effi-
cacious than either therapeutic approach individually. Two exper-
iments were conducted to test the hypothesis; the first consisted of
determining the best dose of buspirone in rats housed in standard
(STD) living conditions, and the second combined the optimal dose
of buspirone with EE to determine potential additive effects.
Methods
Experiment 1: Buspirone dose response
Subjects and surgery. Fifty-two male Sprague-Dawley
pediatric rats (Harlan, Indianapolis, IN) were initially housed
with their dams in a Plexiglas cage and maintained in a tem-
perature (21 – 1C) and light (on 0700 to 1900) controlled en-
vironment. The rats were all postnatal day-17 (PND-17) on the
day of surgery, which consisted of a CCI injury that was pro-
duced as described previously,19,22,28,41,42 with the exception of
some necessary modifications for the smaller rats. Specifically,
surgical anesthesia was induced and maintained with inspired
concentrations of 4% and 2% isoflurane (carried in 2:1 N2O/
O2), respectively, via a nose cone. The rats were secured to a
stereotaxic frame, and core temperature was monitored with a
rectal thermometer and maintained at 37 – 0.5C with a heating
blanket.
Using aseptic procedures, a midline scalp incision was made, the
skin and fascia were reflected to expose the skull, and a craniectomy
was produced in the right hemisphere (between bregma/lambda and
the sagittal suture/coronal ridge) with a high-speed dental drill. The
impact tip (6mm, flat) was lowered and centered through the cra-
niectomy such that it produced a brain injury of moderate severity
(2.2mm tissue deformation at 4m/sec). Immediately after the CCI,
anesthesia was discontinued, and the incision was promptly sutured.
Rats were assessed for acute neurological outcome and placed in a
heated chamber (maintained at 37– 0.5 C) until able to ambulate
freely and then were returned to their dam in the colony. Sham rats
underwent comparable surgical procedures, sans the CCI.
Post-surgery. After surgery, the rats were randomly assigned
to four TBI groups, which are denoted as TBI+ buspirone (0.08mg/
kg; n = 9), TBI + buspirone (0.1mg/kg; n= 9), TBI+ buspirone
(0.3mg/kg; n= 9), TBI+ vehicle (1.0mL/kg; n = 9), and four sham
control groups (n = 16) that received the same doses of buspirone
and vehicle as their TBI counterparts. The pediatric pups were
weaned on PND-28 and pair-housed in standard (STD) steel-wire
mesh cages where they had ad libitum access to rat chow and water.
All experimental procedures were approved by the Institutional
Animal Care and Use Committee at the University of Pittsburgh.
Every attempt was made to minimize discomfort, suffering, and the
number of animals used.
Acute neurological evaluation. Hindlimb reflexive ability
was assessed immediately after the discontinuation of anesthesia by
gently squeezing the rat’s paw every 5 sec and recording the latency
to elicit a withdrawal response. Return of the righting reflex was
determined by recording the time needed for the rat to return to the
prone position after three consecutive supine placements.
Drug administration. Buspirone (Sigma-Aldrich; St. Louis,
MO) was prepared daily by dissolving in sterile saline, which also
served as the vehicle. Buspirone (0.08mg/kg, 0.1mg/kg, or 0.3
mg/kg) and vehicle (1.0mL/kg) were administered intraperitone-
ally (i.p.) beginning 24 h after surgery and once daily for 16 days.
On the days of behavioral testing, the injections were administered
1 h before testing to avoid behavioral symptoms associated with the
serotonin syndrome (e.g., flat body posture) that could affect per-
formance. The doses and route of administration were selected
based on previous data from our laboratory showing a narrow
therapeutic range.25
Cognitive function: spatial learning. Acquisition of spatial
learning was assessed using a Morris water maze (MWM)43 task
that has been shown to be a sensitive indicator of cognitive function
after TBI.23,44–47 The maze consisted of a plastic pool (180 cm
diameter; 60 cm high) filled with tap water (26– 1C) to a depth of
28 cm and situated in a room with prominent visual cues. The
platform was a clear Plexiglas stand (10 cm diameter, 26 cm high)
that was positioned 26 cm from the maze wall in the southwest
quadrant and held constant for each rat.
Spatial learning consisted on providing four blocks of daily trials
(four min intertrial interval) for 5 consecutive days (post-operative
days 11–15) in which the rat was given a maximum of 120 sec to
find the submerged platform (2 cm below the water surface (i.e.,
invisible to the rat). On post-operative day 16, the platform was
raised 2 cm above the water surface (i.e., visible to the rat) as a
control to determine the contributions of nonspatial factors (e.g.,
sensorimotor performance, motivation, and visual acuity) on cog-
nitive performance. Each trial lasted until the rat climbed onto the
platform or the maximum allotted time had elapsed, whichever
occurred first. If the rats did not find the platform within the given
time, they were manually guided to it. All rats remained on the
platform for 30 cumulative sec and then were returned to a heated
incubator between trials. The times of the four daily trials for each
rat were averaged and used in the statistical analyses.
Cognitive function: memory retention. One day after the
final acquisition training session in the MWM (i.e., day 16), all rats
were given a single probe trial to measure memory retention.
During this trial, the platform was removed from the pool, and the
rats were placed in the maze from the location point most distal to
the southwest quadrant (i.e., the ‘‘target quadrant’’ where the
platform was previously located) and allowed to freely explore the
pool for 30 sec and the percent time spent in the target quadrant was
recorded. A spontaneous motor activity recording and tracking
(SMART) system (San Diego Instruments, San Diego, CA) was
used to record the data, which included time to locate the platform
and percent time in the target quadrant.
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Histology: quantification of cortical lesion volume. On
post-operative day 17, the rats were anesthetized with pentobarbital
(50mg/kg, i.p.), and then perfused transcardially with 200mL
0.1M phosphate-buffed saline (pH 7.4) and 300mL 4% parafor-
maldehyde. The brains were extracted, post-fixed in the perfusate
for 1 week, dehydrated with alcohols, and embedded in paraffin
wax. Seven-micrometer-thick coronal sections were cut at 1-mm
intervals throughout the lesion using a rotary microtome and
mounted on gelatin-coated glass microscope slides. After drying at
room temperature, the coronal sections were deparaffinized in
xylenes, rehydrated, and stained with cresyl violet. Cortical lesion
volumes (mm3) were determined by first calculating the area of the
lesion (mm2) by outlining the inferred area of missing cortical
tissue for each section taken at 1-mm intervals (MCID software;
Imagining Research, Ontario, Canada), and then multiplying the
distance between each section (1mm) by the sum of the lesion area
obtained from each section.
Statistical analysis. Data analyses were performed using
StatView 5.0.1 software (Abacus Concepts, Inc., Berkeley, CA) by
observers blinded to treatment conditions. The cognitive data were
analyzed by repeated-measures analysis of variance (ANOVA),
while the acute neurological evaluations, probe trial, swim speed,
and histological data were analyzed by one-factor ANOVAs.When
the ANOVA revealed a significant effect, the Fisher PLSD post-hoc
test was used to determine specific group differences. The results
are expressed as the mean– standard error of the mean (SEM) and
are considered significant when p values are £ 0.05.
Results
Experiment 1: Buspirone dose response
Sham controls did not differ from one another, regardless of
treatments, and thus they were pooled into one group (denoted as
‘‘SHAM’’).
Acute neurological function. No significant differences were
detected among the TBI groups in hindlimb withdrawal response
(right range= 131.7–6.3 sec to 145.9– 5.8 sec; left range= 134.0–
6.4 sec to 149.2– 5.9 sec) or righting ability (range= 217.3– 4.5 sec
to 266.6– 38.9 sec) after the cessation of anesthesia (all p> 0.05).
The lack of significant differences with these acute neurological
indices suggests that all groups experienced equivalent injury se-
verity and level of anesthesia.
Cognitive function: acquisition of spatial learning. Analysis
of the water maze data revealed significant Group (F4,47 = 24.346,
p < 0.0001) and Day (F4,188= 24.464, p< 0.0001) differences, but
no Group ·Day interaction (F16,188 = 1.418, p = 0.14). The post-hoc
analysis revealed that the SHAM group performed significantly
better than all TBI groups, regardless of treatment ( p < 0.0001).
Moreover, the TBI + buspirone (0.1mg/kg) group learned the lo-
cation of the escape platform significantly quicker over the 5 days
of training relative to the TBI + buspirone (0.08mg/kg), TBI+
buspirone (0.3mg/kg), and TBI + vehicle (1.0mL/kg) groups
( p < 0.05; Fig. 1). No other group comparisons were significant
( p > 0.05). Regarding performance on the visible platform task, the
ANOVA revealed a significant group difference (F4,47 = 7.207,
p = 0.0001), which was attributed to the SHAM control needing less
time to reach the platform versus the TBI groups ( p< 0.001), which
did not differ from one another ( p> 0.05).
Cognitive function: probe trial (memory retention). Analysis
of the single probe trial data did not reveal a significant difference
among groups (F4,47 = 2.376, p= 0.052). Closer inspection of the
data with the post-hoc test, however, showed that the SHAM group
performed better than the TBI+ buspirone (0.08mg/kg), TBI+
buspirone (0.3mg/kg), and TBI+ vehicle (1.0mL/kg) groups with
percent times in the target quadrant of 35.9– 4.0 versus 25.4– 3.2,
24.2– 2.3, and 25.3– 1.6, respectively ( p< 0.01). The SHAM group
did not differ from the TBI+ buspirone (0.1mg/kg) group, which
spent 28.7– 1.6% of the allotted time in the target zone ( p= 0.13).
No other group comparisons were statistically different (Fig. 2).
Histology: cortical lesion volume. Analysis of the lesion data
showed a significant difference between the TBI+vehicle (1.0mL/kg)
and TBI+buspirone (0.1mg/kg) groups with mean cortical lesion
volumes of 12.5–2.3 and 5.3–1.5mm3, respectively (p=0.038). No
other group comparisons were statistically different (Fig. 3).
Methods
Experiment 2: Combined therapeutic paradigm:
buspirone +EE
Subjects and surgery. An additional 26 pediatric male rats
were added to this experiment, which consisted of two TBI (n= 9 per
group) and two sham control (n=4 per group) groups denoted as
TBI+vehicle (1.0mL/kg)+EE, TBI+buspirone (0.1mg/kg)+EE,
sham+vehicle (1.0mL/kg)+EE, and sham+buspirone (0.1mg/kg)+
EE. Initial housing, surgery, and weaning were identical to that
described for Experiment 1.
Drug administration. The dose of buspirone for comparison
between the STD and EE groups was selected based on the finding
from Experiment 1 showing that 0.1mg/kg was most effective.
Drug preparation and administration were identical to that de-
scribed for Experiment 1.
FIG. 1. Mean ( – standard error of the mean) time (sec) to locate
a hidden and visible platform in a water maze. For the hidden
platform assessments, *p< 0.05 versus TBI + buspirone (0.08mg/
kg), TBI + buspirone (0.3mg/kg), and TBI + vehicle (1.0mL/kg)
and **p< 0.0001 versus all TBI groups. For the visible platform
assessment, the SHAM group was able to locate the platform
significantly quicker than all TBI groups ( p< 0.001). No other
group comparisons were significant.
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Housing conditions: environmental manipulation. After
weaning (PND-28), the rats were placed in their respective assigned
housing conditions. The EE consisted of specifically designed
36 · 30· 20-inch stainless steel wire cages consisting of three
levels and ladders to ambulate from one level to another such that
interaction with the various toys (e.g., balls, blocks, and tubes),
nesting materials (e.g., paper towels), cage mates, and ad libitum
food and water would be achievable (for depiction of EE cage,
see 20,29). To maintain novelty, the objects were rearranged every
day and changed each time the cage was cleaned, which was twice
per week. Ten rats, which included TBI and sham controls, were
housed together to minimize variability. Rats in the STD conditions
were placed in standard steel wire mesh cages (two rats per cage)
with only food and water available.
Cognitive function: spatial learning and retention. Asse-
ssment of the acquisition of spatial learning and memory retention
was identical to that described for Experiment 1.
Histology: quantification of cortical lesion volume. Methods
were identical to those described for Experiment 1.
Results
Experiment 2: Combined therapeutic paradigm:
buspirone+EE
The sham controls provided buspirone or vehicle and housed in
EE conditions did not differ from the shams in Experiment 1, and
thus they were pooled into one group (denoted as ‘‘SHAM’’).
Acute neurological function. No significant differences were
detected among the TBI groups in hindlimb withdrawal response
(right range = 131.7– 6.3 sec to 147.8– 3.1 sec; left range = 134.0
– 6.4 sec to 151.0 – 3.1 sec) or righting ability (range= 226.9–
13.5 sec to 266.6– 38.9 sec) following the cessation of anesthesia
(all p> 0.05).
Cognitive function: acquisition of spatial learning. Analysis
of the water maze data revealed significant Group (F4,47 = 22.793,
p< 0.0001) and Day (F4,188 = 39.877, p < 0.0001) differences, but
no Group ·Day interaction (F16,188 = 1.238, p= 0.21). The post-hoc
analysis revealed several group differences. The SHAM group
performed significantly better than all TBI groups, regardless of
treatment ( p < 0.009). In addition, the TBI + vehicle (1.0mL/kg) +
EE, TBI + buspirone (0.1mg/kg)+STD, and TBI+ buspirone
(0.1mg/kg) +EE groups learned the location of the escape platform
significantly quicker over the 5 days of training relative to the
TBI+ vehicle (1.0mL/kg) +STD group ( p< 0.05; Fig. 4). More-
over, the TBI + buspirone (0.1mg/kg)+EE group was significantly
better than the TBI + vehicle (1.0mL/kg)+EE and TBI+ buspirone
(0.1mg/kg) +STD groups ( p< 0.05), which did not differ from one
another ( p > 0.05).
Regarding performance on the visible platform task, the ANOVA
revealed a significant Group difference (F4,47= 3.749, p= 0.01),
which was attributed to the SHAM controls needing less time to
reach the platform versus the TBI+ vehicle (1.0mL/kg)+STD,
TBI+ vehicle (1.0mL/kg)+EE, and TBI+ buspirone (0.1mg/kg)+
STD groups ( p< 0.01), but not the TBI+ buspirone (0.1mg/kg)+EE
group ( p= 0.17).
Cognitive function: probe trial (memory retention). Analysis
of the single probe trial data revealed a significant difference
among groups (F4,46 = 4.041, p= 0.007). The differences as delin-
eated by the post-hoc test concluded that the TBI+ buspirone
(0.1mg/kg) +EE group performed better than the TBI + vehicle
(1.0mL/kg) + STD, TBI + vehicle (1.0mL/kg)+EE, and TBI +
buspirone (0.1mg/kg)+ STD groups, with percent times in the
target quadrant of 40.1 – 1.3 versus 25.3 – 1.6, 29.3 – 3.0, and
28.7 – 1.6%, respectively ( p< 0.05). The SHAM group, which
spent 41.1 – 4.7% of the allotted time in the target zone, did not
differ from the TBI+ buspirone (0.1mg/kg)+EE group ( p > 0.05),
FIG. 3. Mean ( –SEM) cortical lesion volume (mm3) at 17 days
after cortical impact injury. *p< 0.05 vs. TBI + vehicle (1.0mL/
kg). No other group comparisons were statistically different.
FIG. 2. Mean (–SEM) percentage of time spent in the target
quadrant (i.e., where platform was previously located) after a single
probe trial 16 days after TBI or sham injury. No significant differ-
ences were observed among the TBI groups ( p> 0.05). **p< 0.01 vs.
TBI+ buspirone (0.08mg/kg), TBI+ buspirone (0.3mg/kg), and
TBI+ vehicle (1.0mL/kg), but not TBI+ buspirone (0.1mg/kg)
( p= 0.13). The dotted line represents performance at the chance
level (25%).
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but was significantly better than all other TBI groups ( p< 0.05). No
other group comparisons were significant (Fig. 5).
Histology: cortical lesion volume. Analysis of the lesion
data revealed that the TBI + vehicle (1.0mL/kg)+EE, TBI+
buspirone (0.1mg/kg)+ STD, and TBI+ buspirone (0.1mg/kg)+
EE groups had smaller cortical lesion volumes relative to the
TBI + vehicle (1.0mL/kg) +STD group with mean lesion volumes
of 3.3 – 1.6mm3, 5.3 – 1.5mm3, 1.4 – 0.6mm3, and 12.5 – 2.3, re-
spectively ( p < 0.05). No other group comparisons were statisti-
cally different (Fig. 6).
Discussion
Serotonin1A (5-HT1A) receptor agonists have been reported to
improve cognitive performance and attenuate histological damage
in adult male rats after CCI injury.18–26 Likewise, EE has also been
shown to confer neurobehavioral and histological benefits in adult
male rats after CCI20,23,26–34 and fluid percussion brain injury.35–40
Recently, the benefits of EE have also been extended to female rats
after CCI.33 Despite the consistent benefits produced by these
therapies in adult rodent models of TBI, they have received limited
attention in pediatric studies. Determining potentially efficacious
therapies for pediatric TBI, which often result from falls or sports-
related activities, is of great concern because it is the leading cause
of death and disability in this age population.6–8
Hence, the aim of this study was to determine whether buspirone,
a 5-HT1A agonist, and EE would enhance cognition and attenuate
histological damage in male pediatric rats. Two experiments were
conducted to test the hypothesis that both treatments would confer
benefits when provided alone and that their combination would be
more efficacious.
The data from Experiment 1 revealed a significant enhancement
in cognitive performance as determined by shorter times to find the
escape platform in a MWM task after treatment with the middle
dose of buspirone (0.1mg/kg). Histological protection was also
observed with the same dose of buspirone as demonstrated by a
significant reduction in cortical lesion volume relative to the vehicle
control group. These findings parallel studies in adult rats in which
FIG. 4. Mean ( – SEM) time (sec) to locate a hidden and visi-
ble platform in a water maze. For the hidden platform assess-
ments, *p < 0.05 versus TBI+ vehicle + STD, ^p < 0.05 versus
TBI + vehicle +EE and TBI + buspirone +STD groups, and
**p < 0.005 versus all TBI groups. For the visible platform as-
sessment, the SHAM group was able to locate the platform
significantly quicker than the TBI + vehicle +STD, TBI + vehi-
cle +EE, and TBI + buspirone+ STD groups ( p < 0.01), but not the
TBI + buspirone +EE group ( p = 0.17). No other group compari-
sons were significant.
FIG. 5. Mean ( – SEM) percentage of time spent in the target
quadrant (i.e., where platform was previously located) after a
single probe trial 16 days after TBI or sham injury. *p < 0.05 vs.
all other TBI groups. **p< 0.05 vs. all TBI groups, except
TBI + buspirone+EE ( p= 0.85). The dotted line represents per-
formance at the chance level (25%).
FIG. 6. Mean ( – SEM) cortical lesion volume (mm3) at 17 days
after cortical impact injury. *p < 0.005 vs. TBI + vehicle +STD.
No other group comparisons were statistically different.
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buspirone and other 5-HT1A receptor agonists (i.e., 8-OH-DPAT)
benefitted neurobehavioral outcome and histology after experimental
TBI.19–25,42 The middle dose of buspirone was also significantly
better than the lowest and highest doses administered (0.08mg/kg
and 0.3mg/kg, respectively) in the acquisition of spatial learning, but
not in memory retention or histological outcome. The narrow dose
response of buspirone in pediatrics is similar to that observed in adult
rats treated with buspirone25 or 8-OH-DPAT19 and in non-TBI
models of cognition.16
Experiment 2 was designed to test the potential additive effect
of the best dose of buspirone from Experiment 1, which in this case
was 0.1mg/kg, and combining it with EE. The data revealed that
the TBI group receiving EE plus vehicle (i.e., EE alone group)
performed significantly better in the acquisition task in the MWM
than the vehicle-treated STD housed group, which replicates nu-
merous studies in adult models of TBI.18–33,36 EE alone, however,
did not lead to an increase in memory retention, which is in con-
trast to that seen in adult models.23,26,29,33 As reported for Ex-
periment 1, the buspirone (0.1mg/kg) STD-housed group was also
significantly better than the STD vehicle group in the MWM. The
data also showed that the combination group (buspirone, 0.1mg/
kg +EE) performed markedly better than the single therapy groups
(i.e., EE plus vehicle and STD buspirone) in both the acquisition of
spatial learning and memory retention, which suggests an additive
effect. This cumulative effect on cognition is novel after CCI
injury because it has not been observed in adult rats using these
therapies.26
Mechanisms for the synergy between EE and buspirone in the
developing versus the adult rodent brain remain undetermined, but
some comments are warranted. Regarding the benefits conferred
by buspirone alone in adult rats, possible mechanisms may include
those previously reported for other 5-HT1A receptor agonists,
such as 8-OH-DPAT and repinotan HCL. It is well known that the
5-HT1A receptor subtype interacts with several neurotransmitter
systems.15–17 Buspirone has been reported to increase dopamine
(DA) levels in regions considered essential for cognitive processing
such as the prefrontal cortex and hippocampus.15,48 In addition, nu-
merous studies have shown that DA neurotransmission is important
for spatial learning and memory (for excellent reviews, see 10–13).
Another potential mechanism may be neuroprotection or resto-
ration of the cholinergic system as evidenced by data showing that
8-OH-DPAT reduced the TBI-induced loss of choline acetyl-
transferase-positive medial septal cells, which correlated with im-
proved cognitive performance.23 Moreover, repinotan HCL has
been shown to increase choline acetyltransferase activity,49 which
is correlated with cholinergic neurotransmission.While the DA and
5-HT systems are significantly developed at the PND age of the
immature rats used in the present study, the acetylcholine system,
however, is not.50 Consequently, the DA systemmay have a greater
role in pediatric rats compared with adults in response to buspirone
treatment alone.
A number of structural and biochemical events have been as-
sociated with EE and plasticity-related reparative responses, such
as increases in neurogenesis, synaptogenesis, dendritic growth/
density, or nerve growth factor51–56 and may contribute, in part, to
the benefits conferred by EE in pediatric rats. In addition, EE at-
tenuates TBI-induced choline acetyltransferase-positive medial
septal cell loss in adult rats,23 but this remains to be evaluated at the
PND age of immature rats used in the present study. This mecha-
nism is similar to that reported for 5-HT1A receptor agonists and
could contribute to the additive cognitive benefit observed with
buspirone plus EE in immature rats if medial septal sparing is
ultimately found. A burst of synaptogenesis and the establishment
of changes in synaptic efficiency associated with memory proces-
sing, however, have been documented at the PND ages used in the
present study,57 which may make the developing brain more sen-
sitive to EE treatment than the adult rat brain and contribute to the
increased efficacy of the combination of EE and buspirone treat-
ment in pediatric versus adult rat populations.
Overall, the data demonstrate that both buspirone and EE can
provide cognitive and histological benefits after pediatric TBI. In
addition, the combination of treatments leads to an additive effect
as demonstrated by cognitive improvement beyond that observed
with the individual therapies, which supports the hypothesis. These
findings may have important rehabilitation-relevant implications
for clinical pediatric TBI. Future studies should build on this initial,
and beneficial, therapeutic approach for pediatric TBI by deter-
mining whether other 5-HT1A receptor agonists can also induce
benefits as well as testing these pharmacotherapies alone or in
conjunction with EE. In addition, to make the treatments even more
clinically relevant, delayed and abbreviated EE studies should be
incorporated into the experimental design as we have been doing in
adult male and female rats after CCI injury.28,30–32
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